Subscribe to RSS
DOI: 10.1055/s-2006-949654
Sequential Amino-Claisen Rearrangement/Intramolecular 1,3-Dipolar Cycloaddition/Reductive Cleavage Approach to the Stereoselective Synthesis of cis-4-Hydroxy-2-aryl-2,3,4,5-tetrahydro-1(1H)-benzazepines
Publication History
Publication Date:
24 August 2006 (online)
Abstract
A novel stereoselective synthesis of cis-2-aryl-4-hydroxy-2,3,4,5-tetrahydro-1-benzazepines from N-allylanilines utilizing aromatic amino-Claisen rearrangement and intramolecular 1,3-dipolar cycloaddition methodologies is described. This sequence involves N-allylation of corresponding N-benzylanilines followed by amino-Claisen rearrangement, subsequent oxidation with in situ 1,3-dipolar cycloaddition affording isoxazolidines, and finally reductive cleavage of the isoxazolidinic N-O bond.
Key words
amino-Claisen rearrangement - intramolecular 1,3-dipolar cycloaddition - tetrahydro-1-benzazepines - ortho-allylanilines - reductive cleavage
-
1a
Shimada Y.Taniguchi N.Matsuhisa A.Sakamoto K.Yatsu T.Tanaka A. Chem. Pharm. Bull. 2000, 48: 1644 -
1b
Kakefuda A.Tsukada J.Kusayama T.Tahara A.Tsukamoto Sh. Bioorg. Med. Chem. Lett. 2002, 229 -
1c
Morita M.Ohkubo-Suzuki A.Takahashi T.Nagashima A.Sawada Y.Ohkawa T.Nishimura Sh.Kita Y. Drug Dev. Res. 2003, 60: 241 -
1d
Tsunoda T.Yamazaki A.Mase T.Sakamoto Sh. Org. Process Res. Dev. 2005, 9: 593 -
1e
Tsunoda T.Yamazaki A.Iwamoto H.Sakamoto Sh. Org. Process Res. Dev. 2003, 7: 883 -
1f
Matthews JM.Greco MN.Hecker LR.Hoekstra WJ.Andrade-Gordon P.de Garavilla L.Demarest KT.Ericson E.Gunnet JW.Hageman W.Look R.Moore JB.Maryanoff BE. Bioorg. Med. Chem. Lett. 2003, 753 -
2a
Martinez A.Castro A.Dorronsoro I.Alonso M. Med. Res. Rev. 2002, 22: 373 -
2b
Zaharevitz DW.Gussio R.Leost M.Senderowicz AM.Lahusen T.Kunick C.Meijer L.Sausville EA. Cancer Res. 1999, 1: 60 -
2c
Schultz C.Link A.Leost M.Zaharevitz DW.Gussio R.Sausville EA.Meijer L.Kunick C. J. Med. Chem. 1999, 42: 2909 -
2d
Sielecki TM.Boylan JF.Benfield PA.Trainor GL. J. Med. Chem. 2000, 43: 2 -
2e
Kunick C.Schultz C.Lemcke T.Zaharevitz DW.Gussio R.Jalluri RK.Sausville EA.Leost M.Meijer L. Bioorg. Med. Chem. Lett. 2000, 567 -
2f
Wieking K.Knockaert M.Leost M.Zaharevitz DW.Meijer L.Kunick C. Arch. Pharm. Pharm. Med. Chem. 2002, 7: 311 -
3a
Schoen WR.Pisano JM.Prendergast K.Wyvratt MJ.Fisher MH.Cheng K.Chan WW.-S.Butler B.Smith RG.Ball RG. J. Med. Chem. 1994, 37: 897 -
3b
DeVita RJ.Wyvratt MJ. Drugs Future 1996, 21: 273 -
3c
DeVita RJ.Bochis R.Frontier AJ.Kotliar A.Fisher MH.Schoen WR.Wyvratt MJ.Cheng K.Chan WW.-S.Butler B.Jacks TM.Hickey GJ.Schleim KD.Leung K.Chen Z.Lee Chiu S.-H.Feeney WP.Cunningham PK.Smith RG. J. Med. Chem. 1998, 41: 1716 -
4a
Guzikowski AP.Cai SX.Espitia SA.Hawkinson JE.Huettner JE.Nogales DF.Tran M.Woodward RM.Weber E.Keana JFW. J. Med. Chem. 1996, 39: 4643 -
4b
Guzikowski AP.Whittemore ER.Woodward RM.Weber E.Keana JFW. J. Med. Chem. 1997, 40: 2424 -
5a
Fray JM.Cooper K.Parry MJ.Richardson K.Steele J. J. Med. Chem. 1995, 38: 3514 -
5b
Nagamatsu T.Hantani Y.Yamada M.Sasaki K.Ohtomo H.Nakayama T.Hirota T. J. Heterocycl. Chem. 1993, 30: 193 -
5c
Nagamatsu T.Hantani Y.Sasaki K.Ohtomo H.Nakayama T.Hirota T. J. Heterocycl. Chem. 1993, 30: 233 - 6
Seto M.Miyamoto N.Aikawa K.Aramaki Y.Kansaki N.Iizawa Y.Baba M.Shiraishi M. Bioorg. Med. Chem. 2005, 13: 363 - 7
Ikemoto T.Ito T.Nishiguchi A.Miura S.Tomimatsu K. Org. Process Res. Dev. 2005, 9: 168 -
8a
Fujita K.Yamamoto K.Yamaguchi R. Org. Lett. 2002, 4: 2691 -
8b
Fujita K.Takahashi Y.Owaki M.Yamamoto K.Yamaguchi R. Org. Lett. 2004, 6: 2785 - 9
Qadir M.Priestley RE.Rising TWDF.Gelbrich T.Coles SJ.Hursthouse MB.Sheldrake PW.Whittall N.Hii (Mimi) KK. Tetrahedron Lett. 2003, 44: 3675 - 10
Omar-Amrani R.Thomas A.Brenner E.Schneider R.Fort Y. Org. Lett. 2003, 5: 2311 -
11a
Qadir M.Cobb J.Sheldrake PW.Whittall N.White AJP.Hii (Mimi) KK.Horton PN.Hursthouse MB. J. Org. Chem. 2005, 70: 1545 -
11b
Dolman SJ.Schrock RR.Hoveyda AH. Org. Lett. 2003, 5: 4899 - 12
Palma A.Barajas JJ.Kouznetsov VV.Stashenko E.Bahsas A.Amaro-Luis JM. Synlett 2004, 2721 - 13
Borch RF.Bernstein MD.Durst HD. J. Am. Chem. Soc. 1971, 93: 2897 - 14
Anderson WK.Lai G. Synthesis 1995, 1287 -
15a
Hamer J.Macaluso A. Chem. Rev. 1964, 64: 473 -
15b
Kametani T.Nagahara T.Honda T. J. Org. Chem. 1985, 50: 2327 -
15c
Mzengeza S.Yang CM.Whitney RA. J. Am. Chem. Soc. 1987, 109: 276 -
15d
Mzengeza S.Whitney RA. J. Org. Chem. 1988, 53: 4074 -
15e
Varlamov A.Kouznetsov V.Zubkov F.Chernyshev A.Shurupova O.Vargas L.Palma A.Rivero J.Rosas A. Synthesis 2002, 771 - 16
Murahashi S.-I.Mitsui H.Shiota T.Tsuda T.Watanabe S. J. Org. Chem. 1990, 55: 1736
References and Notes
NMR data for exo-cycloadduct 4a: 1H NMR (400 MHz, CDCl3): δ = 2.58 (1 H, d, J = 16.5 Hz, 5-HA), 2.61-2.69 (2 H, m, 3-HAHB), 3.45 (1 H, dd, J = 16.6, 5.4 Hz, 5-HB), 4.62 (1 H, dd, J = 11.2, 4.4 Hz, 2-H), 4.97 (1 H, m, 4-H), 7.12 (1 H, dd, J = 6.6, 2.1 Hz, 9-H), 7.15-7.24 (3 H, m, 6-H, 7-H, 8-H), 7.30 (1 H, t, J = 7.6 Hz, 4′-H), 7.39 (2 H, t, J = 7.6 Hz, 3′-H, 5′-H), 7.50 (2 H, d, J = 7.2 Hz, 2′-H, 6′-H). 13C NMR (100 MHz, CDCl3): δ = 34.6 (5-C), 42.7 (3-C), 75.1 (4-C), 75.3 (2-C), 121.9 (9-C), 125.2 (5a-C), 125.9 (7-C), 126.4 (2′-C, 6′-C), 126.5 (8-C), 126.9 (4′-C), 128.4 (3′-C, 5′-C), 129.8 (6-C), 143.8 (1′-C), 150.9 (9a-C).
18NMR data for cis-stereoisomer 5a: 1H NMR (400 MHz, CDCl3): δ = 2.14 (1 H, ddd, J = 11.0, 10.7, 10.5 Hz, 3-Hax), 2.22 (1 H, ddt, J = 11.0, 2.9, 1.9 Hz, 3-Heq), 3.03 (1 H, dt, J = 13.6, 1.9 Hz, 5-Heq), 3.13 (1 H, dd, J = 13.6, 10.5 Hz, 5-Hax), 3.88 (1 H, tdd, J = 10.5, 2.9, 1.9 Hz, 4-Hax), 3.98 (1 H, dd, J = 11.0, 1.9 Hz, 2-Hax), 6.70 (1 H, d, J = 7.6 Hz, 9-H), 6.92 (1 H, t, J = 7.6 Hz, 7-H), 7.10 (1 H, t, J = 7.6 Hz, 8-H), 7.18 (1 H, d, J = 7.6 Hz, 6-H), 7.35 (1 H, t, J = 6.9 Hz, 4′-H), 7.39 (2 H, d, J = 6.9 Hz, 2′-H, 6′-H), 7.43 (2 H, t, J = 6.9 Hz, 3′-H, 5′-H). 13C NMR (100 MHz, CDCl3): δ = 44.7 (5-C), 48.5 (3-C), 61.3 (2-C), 70.0 (4-C), 120.1 (9-C), 121.8 (7-C), 126.6 (2′-C, 6′-C), 127.4 (8-C), 127.8 (4′-C), 128.0 (5a-C), 128.9 (3′-C, 5′-C), 131.6 (6-C), 145.1 (1′-C), 149.4 (9a-C).